BioCentury
ARTICLE | Company News

Regeneron, Neovii Pharmaceuticals deal

September 19, 2016 7:00 AM UTC

Regeneron granted Neovii worldwide rights, except in the U.S. and Japan, to develop and commercialize Arcalyst rilonacept to treat periodic fever syndromes. The company said it will focus initially on familial Mediterranean fever. The recombinant protein with the heterodimeric IL-1 receptor linked to the Fc portion of human IgG is marketed in the U.S. to treat cryopyrin-associated periodic syndromes (CAPS). Neovii declined to provide further details, and Regeneron did not respond to inquiries. ...